Dazodalibep
Dazodalibep (MEDI 4920; VIB 4920) is a non-antibody fusion protein that targets CD40L. Dazodalibep inhibits the co-stimulatory signals between immune cells (such as T cells, B cells, and antigen-presenting cells), thereby enabling the inhibition of a broader range of cellular and humoral responses. Dazodalibep can be used for research on rheumatoid arthritis and Sjögren's syndrome[1][2].
Product Specifications
CAS Number
2245953-10-8
Product Name Alternative
MEDI 4920; VIB 4920
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/dazodalibep.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Dazodalibep]
Molecular Weight
(87.82 kDa)
References & Citations
[1]St Clair EW, et al. CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024 Jun;30 (6) :1583-1592. |[2]Pham TH, et al. AB0746 CD40L BLOCKADE WITH DAZODALIBEP SIGNIFICANTLY IMPROVES DISEASE ACTIVITY, SWOLLEN AND TENDER JOINT COUNTS, WHILE REDUCING MULTIPLE T-AND B-CELL BIOMARKERS IN THE MIDORA PHASE 2 STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 2024 Jun 1;83:1664-5.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC401927 20 µg
Peroxiredoxin 4 (PRDX4) (NM_006406) Human Over-expression Lysate
Sign In for Pricing
View Details 
